CARLSBAD, Calif. –(BUSINESS WIRE)–Jul. 13, 2026– Ionis Pharmaceuticals, Inc.
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
calendar_today
July 13, 2026
person
Ionis Pharmaceuticals, Inc. News Releases
domain
ionis-pharmaceuticals